---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42850987.md"
description: "$VIGONVITA-B(02630.HK) rose by 20%. The oral nucleotide drug VV116 has been confirmed to have significant antiviral activity against the Nipah virus. Coupled with the prior approval from the National Medical Products Administration for Phase III clinical trials, the potential of the antiviral pipeline has been unlocked.As an unprofitable innovative drug listed only at the end of last year, its valuation relies heavily on pipeline milestones. Consequently, it exhibits particularly high elasticity with any positive data. Whether this news-driven surge can continue depends on subsequent clinical progress and indication approvals."
datetime: "2026-07-22T10:08:59.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42850987.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42850987.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42850987.md)
author: "[小仓位过过日子](https://longbridge.com/en/profiles/27571747.md)"
---

# $VIGONVITA-B(02630.HK) rose by 20%. The oral nucle…


### Related Stocks

- [02630.HK](https://longbridge.com/en/quote/02630.HK.md)